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Abstract  
Barber’s palmoplantar pustulosis (PPP) is a form of localised pustular psoriasis, affecting the palmar and plantar 
surfaces. It is a chronic disease, with a deep impact on the patients’ quality of life. The Authors discuss a case of 
Baber Psoriasis successfully treated with monochromatic excimer light. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pustular palmoplantar psoriasis is a peculiar 
form of localised pustular psoriasis occurring on 
palmar and plantar surfaces of the skin (type Barber 
or Barber-Königsbeck). It is a chronic and stubborn 
pathology, difficult to manage and with the tendency 
to recur over time [1]. In contrast to plaque-type 
psoriasis, pustular psoriasis shows homozygous or 
compound heterozygous interleukin-36 (IL36RN) gene 
mutations leading to aberrations in IL-36R antagonist 
function [2]. The immunological peculiarities of 
pustular psoriasis contribute to the less favourable 
outcome of this psoriasis type with tumor-necrosis 
factor-alfa antagonists. Narrow-band ultraviolet-B 
phototherapy (308-311 nm) has been recognised as a 
valid therapeutic option for the disease, leading to 
quick remissions and low recurrence rates. In recent 
years, devices able to deliver the radiation only to 
affected areas of the skin have been developed, with 
the major advantages of sparing unaffected areas of 
the body surface and being more compliant for the 
patients [3].  
 
 
Case Presentation 
 
An otherwise healthy male subject, 38 years 
old, affected by a pustule palmar psoriasis (Fig. 1), 
showed up to our Clinic presenting, on his palms, 
numerous small flat pustules (2-3 mm in diameter), 
whitish to yellowish in colour, on an erythematous 
basis. He lamented a slight, continuous, burning 
sensation. He reported the appearance of these 
lesions about two months before, at first on his left 
palm, and then rapidly spreading to involve also the 
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right palm. He also described how new pustules 
appeared in a few hours, while the older ones were 
creating a yellowish crust which was falling 
spontaneously.  
History for drug assumption was negative, 
and he didn’t report any contact with local irritants. 
The patient didn’t refer any revealing pathology, and 
he showed no familiarity for psoriasis or other skin 
diseases.  
 
Figure 1: Our patient affected by pustular psoriasis on his palms 
 
During the clinical evaluation, no other lesions 
were observed in any other part of the body, apart 
from small, hurting fissurations on the flexural 
surfaces of the wrists, while fingers were not affected. 
Nails showed no sign of psoriatic lesions. A 
rheumatologic evaluation showed no apparent joint 
involvement. Routine blood testing for inflammation 
and infections was negative.  
A punch biopsy performed on a pustular area 
showed subcorneal unilocular pustulosis and a 
neutrophilic infiltration with neutrophilic exocytosis, 
configuring the classical aspect of “spongiform pustule 
of Kogoj”. Moreover, the cultural test showed sterile 
pustules, confirming the initial diagnosis of 
palmoplantar psoriasis (Barber’s palmoplantar 
psoriasis). Narrowband UVB (308-311 nm) is 
considered by dermatologists worldwide an efficient 
treatment for psoriasis [1]. For this reason (and 
according to our positive personal experience), after 
having discussed with the patient about the 
therapeutic possibilities, and after having received his 
informed consent, we decided to perform a focused 
narrowband UVB treatment, using a monochromatic 
excimer light device developed to deliver a 308 nm 
radiation only to the affected areas, thus sparing the 
unaffected surrounding skin. The device emits UVB 
light with the wavelength of 308 nm, with a power 
density of 50 mW/cm
2
 at a distance of 15 cm from the 
skin, and a maximum radiation area of 512 cm
2
.  
The therapeutic procedure schedules two 
sessions in a week for the first four weeks of 
treatment, and then one session in a week for the rest 
of the treatment. During the first session, we 
estimated the MED (Minimal Erythema Dose) of the 
patient in an uninjured part of the body (flexural part of 
the forearm), to be able to set the first dose of 
radiation, corresponding to the MED decreased by 
10%. During the following sessions, we proceeded 
increasing the dose gradually depending on the 
clinical response. Regarding time (seconds of 
irradiation), our patient needed 15 seconds of 
illumination for the first session (0.75 J/cm
2
); the 
duration of the following treatments was increased by 
5 seconds (0.25 J/cm
2
) each time.  
At week 6 (10 treatments), the clinical picture 
was substantially improved, showing a clear reduction 
of inflammation, erythema, desquamation, and the 
complete disappearance of pustules. We decided to 
interrupt the treatment at week twelve (16 total 
sessions) since we evaluated the complete resolution 
of the disease (Fig. 2).  
 
Figure 2: The same patient after the treatment with excimer light 
 
During the entire treatment time, no side 
effects or adverse events were noted. Only a slight, 
transient erythema appeared after each of the first 
four sessions, however leading to no harms or 
discomfort for the patient. Since treatment 
discontinuation, we are monitoring the subject to 
evaluate the possible recurrence of psoriasis. 
However, after 12 weeks without any treatment, no 
lesions are present to date.  
 
 
Discussion 
 
Psoriasis is a chronic inflammatory disease 
involving the skin, and sometimes affecting joints, 
bones, tendons, ligaments, nails, and mucosal 
membranes [1]. About 3% of the Italian population is 
affected by psoriasis, and this percentage reflects the 
worldwide prevalence of the disease [4].  
Psoriasis has many clinical variants, the most 
common of which is the vulgar type (plaque-type), 
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guttate, inverse, mucosal, sebopsoriasis, pustular, 
arthropathic, erythrodermic. Pustular psoriasis can be 
divided into two major clinical variants, localised and 
generalised, both characterised by the same 
elementary lesion, a sterile, non-follicular, superficial 
pustule, but differentiated, among the others, by the 
degree of body surface involvement. Its 
histopathology is characterised by the “spongiform 
pustule of Kogoj”, that is a suppuration pustule located 
in the upper part of spinosus layer and filled with 
neutrophils [5].  
By the localisation of the lesions, and 
depending on their different evolution, two main 
variants of localised pustular psoriasis may be 
distinguished, namely the Barber’s palmoplantar 
pustulosis (PPP) and the Hallopeau’s continuous 
acrodermatitis. PPP is the most common one, and it is 
characterised by the outbreak of little pustules on an 
erythematous and scaly basis, located on the palms of 
the hands and the soles of the feet. Pustules arise by 
rushes in a few hours, are 1 to 5 mm in diameter, and 
are surrounded by an erythematous ring. Usually, they 
are asymptomatic, but they can cause a burning 
sensation. They are flat-topped, whitish to yellowish 
with the tendency to become darker until they dry in a 
couple of days, leaving a crust and a brownish 
hyperpigmentation. Rushes are rapidly arising in the 
acute phase of the disease so that it is possible to 
observe in lesions in several stages of maturation. 
Going ahead with the disease, inflammation and 
erythema may spread to the fingers and the wrists, 
and painful rhagadiform lesions may appear.  
PPP mainly occurs in middle-aged persons, 
more often females, even if we can’t rule out a more 
premature exordium in child’s age. Even if in around 
half of the patients, the disease can start with 
unilateral lesions, it is any way inclined to be 
symmetrically present on the extremities. The 
presence (contemporary or diachronic) in the same 
subject of pustular lesions together with lesions 
peculiar of other forms of psoriasis is not unusual, 
even if the real incidence of this association is still 
discussed [6, 7]. 
PPP can be associated with osteoarthritis, in 
a multifocal recurrent chronic form (CRMO) [8] or the 
sternocostoclavicular hyperostosis (SCCH), in this last 
case configuring the so-called SAPHO (Synovitis, 
Acne, Pustulosis, Hyperostosis, Osteomyelitis) 
syndrome [9].  
The diagnosis of PPP is essentially clinical, 
possibly held up by laboratory studies; though these 
may be usually insignificant (there is the possibility of 
a transitory neutrophilic leucocytosis). Histopathology 
of the lesions shows different aspects according to the 
stage of the disease. In the initial phase, 
intraepidermal vesicles containing mononuclear cells 
may be seen, caused by focal spongiosis. With the 
evolution of the lesion, neutrophils can be seen inside 
the vesicles, leading to the development of the typical 
subcorneal pustules in the latter phase. Usually, a 
cultural test of the pustulosis gives a negative result 
(sterile pustules). Many therapeutic options are 
nowadays available for PPP; however, none of them 
can be addressed to as the gold standard treatment 
[10].  
Topical high potency corticosteroids, alone or 
in association with salicylic acid or vitamin D 
analogues, are still considered the best treatment for 
PPP [11]. This approach is effective in a large 
percentage of patients, yet doesn’t seem to possess 
the capability for a long-term control of the disease 
doesn’t prevent the recurrences, and the event of 
tachyphylaxis and side effects are major 
contraindications for its continuous use [12]. Better 
results can be obtained with systemic corticosteroids 
[13] and with oral acitretin [14], but the possible side 
effects, and the worsening of psoriasis that can be 
experienced early after their interruption makes them 
desirable only for particularly selected cases. Oral 
colchicine [15] leads to good results, but its use is 
limited by side effects like diarrhoea and nausea. 
Systemic cyclosporine A has proven efficacy in the 
control of the disease [16], but quick relapses after its 
interruption and the well-known collateral effects 
connected by the intrinsic characteristics of the drug 
(arterial hypertension, renal insufficiency, nausea and 
tiredness) limit its use [17]. A few studies quest for the 
possibility to recur to local administration of 
methotrexate-based gel [18], but the experience is still 
anecdotic.  
In recent years, the new biological therapies 
(monoclonal antibodies, receptor fusion proteins and 
similar) have been developed to manage psoriasis in 
its inner mechanisms of immune regulation. In the 
clinical experiences with these new generation drugs, 
there are some reports of PPP successfully treated 
with efalizumab, alefacept, infliximab, adalimumab, 
and etanercept [10]. However, the legal (i.e. FDA and 
EMA-approved use of biologics in psoriasis) and 
scientific limitations (i.e. guidelines) for the use of 
biologics, together with the major possible medical 
involvements connected to this category of 
therapeutic agents, make of them a treatment 
dedicated to a few well-chosen patients and it is off-
label.  
Among the physical therapies, PUVA therapy, 
probably in association with oral retinoids (RePUVA) 
[19] has been used for pustular psoriasis.  
The efficacy of UVB light in psoriasis has 
been largely demonstrated (10, 11, 19) so that 
nowadays UVB treatment may be considered the first-
line treatment in many forms of psoriasis. UVB 
treatments can be safely used in pregnant women and 
children, and are related to less erythema in respect 
of UVA, no phototoxic effects and no epidermal 
thickening after long-term irradiation. No statistical 
differences have been shown between PUVA and 
UVB regarding success rates [19].  
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However, during the last years focused 
phototherapy with narrowband UVB (307-311 nm) 
showed a similar efficacy, but without a risk of 
secondary skin cancer development [21-24]. This 
therapeutical approach considers that psoriasis 
patients undergoing phototherapy usually receive high 
cumulative doses of radiation during their lives, thus 
leading to secondary cutaneous disorders, like 
photoaging, teleangectasias, excessive tanning, etc. 
On the contrary, a phototherapic device capable of 
delivering the UV-radiation only to affected areas 
could lower all these collateral effects dramatically 
decreasing the total dose of radiation. Moreover, the 
treatment may be tailored to each affected area with 
different doses of UV.  
The monochromatic excimer light (MEL) 
device delivers a UVB wavelength at 308 nm only to 
the lesional skin, and seems particularly effective for 
variants of psoriasis were the involvement of the skin 
is lower than 20-25% of the total body surface. Its high 
potency (up to 4.5 J/cm
2
) and subsequently the need 
for short time of irradiation, together with the 
possibility to schedule just 1 session per week, makes 
MEL mostly appreciated to a large part of patients, 
thus increasing treatment compliance, which is 
particularly useful when we have to deal with long-
lasting therapeutic protocols. Finally, the possibility to 
focus the radiations on skin lesions reduces the risks 
of acute and chronic side effects in the uninvolved 
safe skin.  
In conclusion, our experience scores another 
point in favour of focused narrowband UVB treatments 
for localised psoriasis, showing once more its efficacy, 
relative rapidity of action and safety. Moreover, in our 
opinion, the efficacy of MEL on localised pustular 
psoriasis, a challenging clinical picture, which 
management is often difficult both for the patient and 
the dermatologist, makes it one of the best weapons 
we have to fight, and win, against this disease.  
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